670253-37-9

Usage

Uses

Used in Pharmaceutical Industry:
2-Pyridinamine, 4-chloro-5-iodois used as an intermediate in the synthesis of various pharmaceuticals. Its unique structure and properties make it a valuable building block for the development of new drugs with potential therapeutic applications.
Used in Agrochemical Industry:
2-Pyridinamine, 4-chloro-5-iodois also used as an intermediate in the synthesis of agrochemicals. Its presence in these compounds can contribute to the development of new pesticides or other agricultural products that can improve crop protection and yield.
In both industries, the use of 2-Pyridinamine, 4-chloro-5-iodoas an intermediate allows for the creation of a wide range of products with specific applications, leveraging its unique chemical properties to achieve desired effects in medicine and agriculture.

InChI:InChI=1/C5H4ClIN2/c6-3-1-5(8)9-2-4(3)7/h1-2H,(H2,8,9)

Upstream product

• 19798-80-2 2-Amino-4-chloropyridine 

Downstream Products

• 1261493-38-2 4-chloro-6-methoxy-nicotinonitrile 
• 1708975-10-3 6-amino-4-((2-methoxyethyl)amino)nicotinonitrile 
• 343781-49-7 2,4-dichloro-5-iodopyridine 
• 1621000-13-2 6-amino-4-phenylniconitrile 
• 670253-38-0 6-amino-4-chloronicotinonitrile 
• 1445151-14-3 6-(3-ethylureido)-N-m-tolyl-4-(m-tolylamino)nicotinamide 
• 1445153-74-1 6-amino-N-(3-methylphenyl)-4-[(3-methylphenyl)amino]pyridine-3-carboxamide 

Relevant academic research and scientific papers

High-selectivity fibroblast growth factor receptor inhibitor and application

The invention discloses a high-selectivity fibroblast growth factor receptor inhibitor and application, and particularly relates to a compound shown in a formula (I) or a pharmaceutically acceptable salt, a solvate, a geometric isomer, a stereoisomer, a tautomer and any mixture thereof. The compound shown in the formula (I) or the pharmaceutically acceptable salt, the solvate and the pharmaceutical composition thereof can be applied to prevention or treatment of diseases related to FGFR4 activity or overexpression, and can also be combined with other medicines to be used for treating various related diseases, especially for treating various cancers, wherein the cancers may be liver cancer, lung cancer, gastric cancer, breast cancer, ovarian cancer, prostate cancer, renal cell carcinoma, skin cancer, colon cancer, bile duct cancer, glioma or sarcoma.

Halogen acid salt product of urea compound, and preparation method thereof

The invention particularly relates to a salt of a urea compound, and a preparation method thereof. According to the method, an organic solvent and water mixed crystallization solvent system is adopted, an free alkali and an acid are paired to form ion pairs, crystallization is conducted, and then heat preservation pulping crystallization is conducted within a certain temperature range to obtain the novel crystal form, wherein the product is high in solubility in water, simple in preparation method, high in yield, stable in property and easy to store, transport and use in the later period. Thepreparation method provided by the invention is good in process reproducibility, simple to operate and suitable for industrial production.

Novel crystal form product of urea compound, and preparation method thereof

The invention particularly relates to a novel crystal form of a urea compound, and a preparation method thereof. According to the method, an organic solvent crystallization solvent system is adopted,an free alkali and an acid are paired to form ion pairs, crystallization is conducted, and then heat preservation pulping crystallization is conducted within a certain temperature range to obtain thenovel crystal form, wherein the crystal form product is high in water solubility, simple in preparation method, high in yield, stable in property and easy to store, transport and use in the later period. The preparation method provided by the invention is good in process reproducibility, simple to operate and suitable for industrial production.

Malate product of urea compound, and preparation method thereof

The invention particularly relates to a salt of a urea compound, and a preparation method thereof. According to the method, an organic solvent and water mixed crystallization solvent system is adopted, an free alkali and an acid are paired to form ion pairs, crystallization is conducted, and then heat preservation pulping crystallization is conducted within a certain temperature range to the novelcrystal form, wherein the product is high in solubility in water, simple in preparation method, high in yield, stable in property and easy to store, transport and use in the later period. The preparation method provided by the invention is good in process reproducibility, simple to operate and suitable for industrial production.

A class of intermediates for preparing anticancer drugs

The invention discloses a raw material for synthesizing an anticancer drug, and a key intermediate for synthesizing an anticancer drug. The invention further discloses a preparation method of an anticancer drug. According to the present invention, the syn

COMPOUND FOR SELECTIVELY INHIBITING KINASE AND USE THEREOF

Provided are a compound of formula (I), a stereoisomer, a tautomer or a pharmaceutically acceptable salt thereof, use thereof as a selective inhibitor for FGFR4 kinase and use thereof in manufacturing a medicament or pharmaceutical composition for treating diseases due to FGFR4 or FGF19. The compound disclosed by the invention has selective and significant inhibitory activities against FGFR4, and has wide application prospect in the field of tumor treatment.

The Rational Design of Selective Benzoxazepin Inhibitors of the α-Isoform of Phosphoinositide 3-Kinase Culminating in the Identification of (S)-2-((2-(1-Isopropyl-1H-1,2,4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)oxy)propanamide (

Inhibitors of the class I phosphoinositide 3-kinase (PI3K) isoform PI3Kα have received substantial attention for their potential use in cancer therapy. Despite the particular attraction of targeting PI3Kα, achieving selectivity for the inhibition of this

NEW SUBSTITUTED BIPHENYL ANALOGUES AS DUAL INHIBITORS OF AROMATASE AND SULFATASE

Provided are new biphenyl derivatives of formula (Ia). These compounds act as aromatase and sulfatase inhibitors. They are particularly useful for treating pathological conditions or diseases in which aromatase and sulfatase are involved. Moreover, provided are processes for the preparation of these compounds and pharmaceutical compositions containing said products and their use for the preparation of a medicament, in particular for the treatment of diseases characterized by aromatase and sulfatase activity such as hormone-dependent cancers.

Synthesis and pharmacological evaluation of 6-aminonicotinic acid analogues as novel GABAA receptor agonists

A series of 6-aminonicotinic acid analogues have been synthesized and pharmacologically characterized at native and selected recombinant GABA A receptors. 6-Aminonicotinic acid (3) as well as 2- and 4-alkylated analogues (9-11, 14-16) display low to mid-micromolar GABAAR binding affinities to native GABAA receptors (Ki 1.1-24 μM). The tetrahydropyridine analogue of 3 (22) shows low-nanomolar affinity (K i 0.044 μM) and equipotency as an agonist to GABA itself as well as the standard GABAA agonist isoguvacine. Cavities surrounding the core of the GABA binding pocket were predicted by molecular interaction field calculations and docking studies in a α1β 2γ2 GABAA receptor homology model, and were confirmed by affinities of substituted analogues of 3. The tight steric requirements observed for the remarkably few GABAAR agonists reported to date is challenged by our findings. New openings for agonist design are proposed which potentially could facilitate the exploration of different pharmacological profiles within the GABAAR area.

Pyridine-3-carboxamide-6-yl-ureas as novel inhibitors of bacterial DNA gyrase: Structure based design, synthesis, SAR and antimicrobial activity

The development of antibacterial drugs based on novel chemotypes is essential to the future management of serious drug resistant infections. We herein report the design, synthesis and SAR of a novel series of N-ethylurea inhibitors based on a pyridine-3-carboxamide scaffold targeting the ATPase sub-unit of DNA gyrase. Consideration of structural aspects of the GyrB ATPase site has aided the development of this series resulting in derivatives that demonstrate excellent enzyme inhibitory activity coupled to potent Gram positive antibacterial efficacy.